[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy  Davis M.B.A.", "title": "SVP of Cardiovascular & Head of Metabolic Franchise", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nadia  Meshkova M.B.A.", "title": "VP & Treasurer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 15.62, "open": 15.79, "dayLow": 14.93, "dayHigh": 15.9208, "regularMarketPreviousClose": 15.62, "regularMarketOpen": 15.79, "regularMarketDayLow": 14.93, "regularMarketDayHigh": 15.9208, "payoutRatio": 0.0, "beta": 0.953, "forwardPE": -3.6303318, "volume": 1979019, "regularMarketVolume": 1979019, "averageVolume": 1846401, "averageVolume10days": 1547470, "averageDailyVolume10Day": 1547470, "bid": 11.38, "ask": 19.11, "bidSize": 2, "askSize": 1, "marketCap": 2115691904, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 30.41, "priceToSalesTrailing12Months": 3.880515, "fiftyDayAverage": 14.5314, "twoHundredDayAverage": 18.115725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1761807616, "profitMargins": -0.26406, "floatShares": 120895883, "sharesOutstanding": 138100000, "sharesShort": 13310190, "sharesShortPriorMonth": 13527313, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.0964, "heldPercentInsiders": 0.13018, "heldPercentInstitutions": 0.77219003, "shortRatio": 7.27, "shortPercentOfFloat": 0.1244, "impliedSharesOutstanding": 138100000, "bookValue": 4.949, "priceToBook": 3.0955749, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -143968992, "trailingEps": -1.24, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 3.231, "enterpriseToEbitda": -18.083, "52WeekChange": -0.4375918, "SandP52WeekChange": 0.09544468, "quoteType": "EQUITY", "currentPrice": 15.32, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 44.0, "targetMedianPrice": 39.5, "recommendationMean": 1.86667, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 1095309056, "totalCashPerShare": 7.931, "ebitda": -97428000, "totalDebt": 740513984, "quickRatio": 4.977, "currentRatio": 5.147, "totalRevenue": 545209024, "debtToEquity": 108.227, "revenuePerShare": 4.305, "returnOnAssets": -0.05861, "returnOnEquity": -0.26224002, "grossProfits": 545209024, "freeCashflow": -6458500, "operatingCashflow": 61147000, "grossMargins": 1.0, "ebitdaMargins": -0.17870001, "operatingMargins": 0.70241, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": -1.92062, "regularMarketPrice": 15.32, "postMarketTime": 1750451945, "regularMarketTime": 1750449601, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "market": "us_market", "esgPopulated": false, "postMarketChangePercent": 1.5013088, "postMarketPrice": 15.55, "postMarketChange": 0.2300005, "regularMarketChange": -0.3, "regularMarketDayRange": "14.93 - 15.9208", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1846401, "fiftyTwoWeekLowChange": 5.75, "fiftyTwoWeekLowChangePercent": 0.600836, "fiftyTwoWeekRange": "9.57 - 30.41", "fiftyTwoWeekHighChange": -15.09, "fiftyTwoWeekHighChangePercent": -0.49621835, "fiftyTwoWeekChangePercent": -43.75918, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754510400, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1747081800, "earningsCallTimestampEnd": 1747081800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.24, "epsForward": -4.22, "epsCurrentYear": -0.17868, "priceEpsCurrentYear": -85.73987, "fiftyDayAverageChange": 0.78859997, "fiftyDayAverageChangePercent": 0.054268684, "twoHundredDayAverageChange": -2.7957249, "twoHundredDayAverageChangePercent": -0.15432587, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "corporateActions": [], "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-06-21"}]